Scholarlink

Introduction <p>Retrospective, longitudinal analysis of sham observed eyes from the phase&#xa0;3 OAKS and DERBY trials evaluated the relationship between geographic atrophy (GA) growth and the presence or absence of outer retinal tubulation (ORT).</p> Methods <p>Prevalence rates of ORT were calculated, and analysis of GA growth was performed using fundus autofluorescence and optical coherence tomography (OCT).</p> Results <p>ORT prevalence rates were 32%, 37.5%, and 43% at baseline, month&#xa0;12, and month&#xa0;24, respectively. Eyes with a fully formed ORT at baseline had 23.6% less GA area growth over 24&#xa0;months compared with GA without ORT present at baseline.</p> Conclusion <p>The presence of ORT at baseline on OCT may be reflective of slower growth of GA, irrespective of GA location, as was noted in this series. The potential diagnostic impact of ORT should be considered when designing clinical studies for GA and when analyzing the results of such studies.</p> Trial registration <p>OAKS: ClinicalTrials.gov identifier NCT03525613 (registered May&#xa0;15, 2018); EudraCT identifier 2018-001435-52 (registered September 27, 2018). DERBY: ClinicalTrials.gov identifier NCT03525600 (registered May&#xa0;15, 2018); EudraCT identifier 2018-001436-22 (registered September 21, 2018).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outer Retinal Tubulation and Geographic Atrophy: A Natural History Analysis of Sham Observed Eyes from the OAKS and DERBY Trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月19日

查看全文
  • Srinivas Sadda,
  • Kensington A. Hatcher,
  • Birva K. Shah,
  • Srinivas Sai Kondapalli,
  • Chao Li,
  • Caroline R. Baumal

摘要

Introduction

Retrospective, longitudinal analysis of sham observed eyes from the phase 3 OAKS and DERBY trials evaluated the relationship between geographic atrophy (GA) growth and the presence or absence of outer retinal tubulation (ORT).

Methods

Prevalence rates of ORT were calculated, and analysis of GA growth was performed using fundus autofluorescence and optical coherence tomography (OCT).

Results

ORT prevalence rates were 32%, 37.5%, and 43% at baseline, month 12, and month 24, respectively. Eyes with a fully formed ORT at baseline had 23.6% less GA area growth over 24 months compared with GA without ORT present at baseline.

Conclusion

The presence of ORT at baseline on OCT may be reflective of slower growth of GA, irrespective of GA location, as was noted in this series. The potential diagnostic impact of ORT should be considered when designing clinical studies for GA and when analyzing the results of such studies.

Trial registration

OAKS: ClinicalTrials.gov identifier NCT03525613 (registered May 15, 2018); EudraCT identifier 2018-001435-52 (registered September 27, 2018). DERBY: ClinicalTrials.gov identifier NCT03525600 (registered May 15, 2018); EudraCT identifier 2018-001436-22 (registered September 21, 2018).